Dostinex Use In Pregnancy & Lactation

Animal studies with cabergoline have not demonstrated teratogenic effects or effects on overall reproductive performance. However, there are no adequate and well-controlled studies in pregnant women. Cabergoline should be used during pregnancy only if clearly needed. If conception occurs during therapy with cabergoline, discontinuation of treatment should be considered, after careful evaluation of the risks and benefits to mother and fetus. Pregnancy should be avoided for at least one month following discontinuation of treatment with cabergoline due to the long half-life of the drug and the limited data on in utero exposure, although the use of cabergoline at 0.5 to 2 mg/week for hyperprolactinemic disorders does not appear to be associated with an increased risk of abortion, premature delivery, multiple pregnancy or congenital abnormalities (See Treatment of Hyperprolactinemic Disorders under Precautions).
In rats, cabergoline and/or its metabolites are excreted in milk. No information is available on the excretion in breast milk in humans; however, mothers should be advised not to breast-feed in case of failed lactation inhibition/suppression by cabergoline. Since it prevents lactation, cabergoline should not be administered to mothers with hyperprolactinemic disorders who wish to breast-feed their infants.